U.S. Markets open in 7 hrs 58 mins

Evaxion Biotech A/S (EVAX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.50+0.18 (+3.38%)
At close: 4:00PM EDT

Evaxion Biotech A/S

Dr. Neergaards Vej 5f DK
Hoersholm 2970
Denmark
45 53 53 18 50
http://www.evaxion-biotech.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees35

Key Executives

NameTitlePayExercisedYear Born
Dr. Lars Aage-Staal Wegner M.D.Chief Exec. Officer942kN/A1975
Dr. Niels Iversen Moeller M.D.Co-founder & Chief Bus. Officer213kN/A1979
Mr. Andreas Holm MattssonCo-Founder & Chief Innovation Officer213kN/A1976
Mr. Glenn S. VraniakChief Financial Officer1.44MN/A1963
Dr. Jürgen Langhärig EMBA, Ph.D.Head of Bus. Devel.N/AN/AN/A
Dr. Erik Deichmann Heegaard DMSC, M.D., Ph.D.Chief Medical OfficerN/AN/A1968
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Evaxion Biotech A/S, a clinical-stage artificial intelligence-immunology platform company, identifies and develops novel immunotherapies for the treatment of various cancers, bacterial diseases, and viral infections. The company develops therapies using PIONEER, an immuno-oncology platform; EDEN, a bacterial disease platform; and RAVENTM, a viral disease platform. It develops EVX-01, a novel liposomal, peptide-based cancer immunotherapy that is in clinical Phase I/IIa trial for indications, such as metastatic and/or unresectable melanoma, non-small cell lung cancer, and bladder cancer; EVX-02, a novel, DNA-based cancer immunotherapy that is in Phase I/IIa trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, a DNA-based neoepitope immunotherapy, which is in late pre-clinical development for the treatment of various cancers, as well as EVX-B1, a multi-component subunit vaccine, which is in pre-clinical development for the prevention of S. aureus induced skin and soft tissue infections in patients undergoing hernia surgery. The company has collaboration agreements with National Center for Cancer Immune Therapy (CCIT-DK) at Herlev Hospital, Department of Health Technology at Danish Technical University, Center for Genomic Medicine at University Hospital Copenhagen, and the Center for Vaccine Research at SSI for the development and Phase 1/2a clinical trial of its EVX-01 product candidate. Evaxion Biotech A/S was incorporated in 2008 and is headquartered in Hoersholm, Denmark.

Corporate Governance

Evaxion Biotech A/S’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.